Resumo

MATTAR, Denise et al. 5-Fluorouracilo y cisplatino en carcinoma localmente avanzado del conducto anal: Resultados preliminares. Rev. venez. oncol. [online]. 2007, vol.19, n.4, pp.277-286. ISSN 0798-0582.

OBJECTIVE: A 65 % 5 year indices of disease free survival rates from scheme 5- fluorouracilo /mitomycin/ radiation in advanced anal carcinoma needs to improvement. The purpose of these works is determining the response to new scheme of neoadjuvant chemotherapy and concomitant radiotherapy for locally advanced anal canal squamous cell carcinoma. METHODS: Of 60 patients accrued from 2001 to 2005, 37 were analyzable and included in this study. The median age was 57 years, with women predominated (73 %). Twenty five patients (67 %) presented a >5 cm tumor diameter and 57 % had clinically lymphatic nodules compromises. Two induction and two concomitant cycles were administrative of 5- fluorouracil (1 000 mg/m² days 1-5, and 21-25, plus cisplatin (100 mg/m² on days 1 and 21) with two cycles of 5-fluouracil (1 000 mg/m² 42-46 y 63 67) days and mitomycin (10 mg/m² days 42 and 63) concurrent with radiation therapy (45 to 59 Gy; start the day 42) during six weeks (weeks 7 to 12). RESULTS: At a median followup period regiment average of 21 months, complete response was achieved in 20 (54 %) patients, partial response in 15 (41 %) patients, disease free survival was 27 % and colostomy disease free survival rate was 35 %. Grade 3/4 toxicity rates: non-hematologic = 32 % and hematologic = 54 %. CONCLUSIONS: Induction with 5- fluorouracilo /cisplatin followed by 5- fluorouracilo / mitomycin/radiation is effective for anal sphincter preservation and the local control as standard approach.

Palavras-chave : Carcinoma; ano; squamous cell; induction; radiotherapy; chemotherapy; cisplatinum; 5-fluouracil.